Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Vectus Biosystems Limited ( (AU:VBS) ).
Vectus Biosystems has issued 25,000 new fully paid ordinary shares following the exercise of vested options granted under its Employee Incentive Plan by two of the company’s contractors, slightly increasing its share capital base. The company confirmed the issuance was conducted without a prospectus under relevant Corporations Act provisions and that it remains compliant with its financial reporting and continuous disclosure obligations, signalling routine corporate housekeeping with limited immediate impact on broader operations or shareholder structure.
The most recent analyst rating on (AU:VBS) stock is a Hold with a A$0.10 price target. To see the full list of analyst forecasts on Vectus Biosystems Limited stock, see the AU:VBS Stock Forecast page.
More about Vectus Biosystems Limited
Vectus Biosystems Limited (ASX: VBS) is an Australian biotechnology company focused on developing pharmaceutical and medical solutions, operating within the life sciences sector and listed on the Australian Securities Exchange, where it regularly uses equity-based incentive structures to engage employees and contractors.
Average Trading Volume: 95,158
Technical Sentiment Signal: Sell
Current Market Cap: A$5.87M
Find detailed analytics on VBS stock on TipRanks’ Stock Analysis page.